Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

@article{Attal2019IsatuximabPP,
  title={Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study},
  author={M. Attal and P. Richardson and S. Rajkumar and J. San-Miguel and ICARIA-MM study group},
  journal={The Lancet},
  year={2019},
  volume={394},
  pages={2096-2107}
}
BACKGROUND Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and… Expand
100 Citations

Paper Mentions

Interventional Clinical Trial
Primary Objective: To demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS… Expand
ConditionsPlasma Cell Myeloma
InterventionDrug
Isatuximab for the treatment of relapsed/refractory multiple myeloma
  • 1
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
...
1
2
3
4
...